TY - JOUR
T1 - Antiplatelet effects of prostacyclin analogues
T2 - Which one to choose in case of thrombosis or bleeding?
AU - Rogula, Sylwester P.
AU - Mutwil, Hubert M.
AU - Gąsecka, Aleksandra
AU - Kurzyna, Marcin
AU - Filipiak, Krzysztof J.
PY - 2021
Y1 - 2021
N2 - Prostacyclin and analogues are successfully used in the treatment of pulmonary arterial hypertension (PAH) due to their vasodilatory effect on pulmonary arteries. Besides vasodilatory effect, prostacyclin analogues inhibit platelets, but their antiplatelet effect is not thoroughly established. The antiplatelet effect of prostacyclin analogues may be beneficial in case of increased risk of thromboembolic events, or undesirable in case of increased risk of bleeding. Since prostacyclin and analogues differ regarding their potency and form of administration, they might also inhibit platelets to a different extent. This review summarizes the recent evidence on the antiplatelet effects of prostacyclin and analogue in the treatment of PAH, this is important to consider when choosing the optimal treatment regimen in tailoring to an individual patients' needs.
AB - Prostacyclin and analogues are successfully used in the treatment of pulmonary arterial hypertension (PAH) due to their vasodilatory effect on pulmonary arteries. Besides vasodilatory effect, prostacyclin analogues inhibit platelets, but their antiplatelet effect is not thoroughly established. The antiplatelet effect of prostacyclin analogues may be beneficial in case of increased risk of thromboembolic events, or undesirable in case of increased risk of bleeding. Since prostacyclin and analogues differ regarding their potency and form of administration, they might also inhibit platelets to a different extent. This review summarizes the recent evidence on the antiplatelet effects of prostacyclin and analogue in the treatment of PAH, this is important to consider when choosing the optimal treatment regimen in tailoring to an individual patients' needs.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123325807&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/33200814
U2 - https://doi.org/10.5603/CJ.a2020.0164
DO - https://doi.org/10.5603/CJ.a2020.0164
M3 - Article
C2 - 33200814
VL - 28
SP - 954
EP - 961
JO - Cardiology journal
JF - Cardiology journal
SN - 1898-018X
IS - 6
ER -